Smart Im­mune picks up $5M from Gates Foun­da­tion; Ox­ford Nanopore teams up with French di­ag­nos­tics play­er

French biotech Smart Im­mune has been hand­ed an eq­ui­ty in­vest­ment of $5 mil­lion from the Bill & Melin­da Gates Foun­da­tion.

The cash will specif­i­cal­ly go to ad­vanc­ing a new Phase I/II clin­i­cal tri­al for Smart Im­mune’s lead as­set, called SMART 101. The drug can­di­date will be used in pa­tients with acute leukemia, with the even­tu­al goal of de­vel­op­ing and re­leas­ing an HIV-re­sis­tant cell ther­a­py prod­uct.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN